人白细胞干扰素和基因工程干扰素α-1b治疗慢性乙型肝炎

目的：比较人白细胞干扰素（ＬＩＦＮ）和基因工程干扰素α－１ｂ（ｒＩＦＮα－１ｂ）治疗慢性乙型肝炎（ＣＨＢ）的疗效和不良反应。方法：ＣＨＢ病人８３例（男性６９例，女性１４例；年龄３２±ｓ８ａ）。Ａ组２９例，用ＬＩＦＮ３ＭＵ；Ｂ组２７例，用ｒＩＦＮα－１ｂ３ＭＵ，Ｃ组２７例用人血浆白蛋白冻干制品１０ｇ，３组均ｉｍ，ｑｄ×４ｗｋ，继以ｑｏｄ×８ｗｋ。结果：３组ＨＢｅＡｇ阴转率分别为３８％，４１％，７％；ＨＢＶ－ＤＮＡ阴转率分别为４０％，５２％，７％。Ａ和Ｂ组ＩＦＮ对ＨＢＶ复制的抑制作用显著优于Ｃ组（Ｐ＜０．０５），但Ａ和Ｂ组间无显著差异。Ａ组不良反应显著大于Ｂ组（Ｐ＜０．０５）。结论：２种不同来源的ＩＦＮ治疗ＣＨＢ均有显著疗效，２药无显著差别，但Ａ组不良反应明显。

Treatment of chronic hepatitis B with human leukocyte interferon and recombinant interferon α-1b

AIM: To compare the efficacies and adverse reactions between human leukocyte interferon (LIFN) and recombinant interferon α-1b (rIFN α-1b ) in treatment of chronic hepatities B (CHB). METHODS: Patients (n=83, M 69, F 14; age 32±s 8 a) with biopsy-proven CHB were randomly allocated into 3 groups; (A) 29 patients were treated with LIFN 3 MU; (B) 27 patients with rIFN α-1b 3 MU; (C) 27 patients served as control with human albumin 10 g, im qd×4 wk, followed by qod×8 wk. RESULTS: The seroconversion rates of HBeAg and HBV-DNA for 3 groups were 38%, 41%, 7% and 40%, 52%, 7%, respectively. There was difference between treated and untreated groups of IFN (P<0.05), but no significant different was found between group A and group B. The adverse reactions were more obvious in group A than those in group B (P<0.05). CONCLUSION: LIFN and rIFN α-1b have therapeutic effects on CHB. LIFN does not get better than rIFN α-1b with respect of the efficacy in therapy of CHB based on the same dose. But the adverse reactions are more obvious in LIFN recipients than in rIFN α-1b recipients.